The GPhC said:

“Children born to women who take valproate during pregnancy are at significant risk of birth defects and persistent developmental disorders. As such, it is vital that women and girls are dispensed valproate safely. The GPhC is reminding all pharmacy professionals of what they must do to ensure women and girls receive the right information about valproate and the risk of birth defects.”

Regulatory Action

The GPhC said in the email to pharmacy professionals:

We have recently investigated instances of pharmacies where valproate has been dispensed in a white box with no safety warnings or Patient Information Leaflet. Our Inspectors have followed up with these pharmacies and their Superintendents to make sure they understand what went wrong, that procedures are reviewed and that the whole pharmacy team is made aware of how to dispense valproate safety.

Insight Works Training